+
Covestro Begins Local Medical-Grade TPU Production in Taiwan
ECONOMY & POLICY

Covestro Begins Local Medical-Grade TPU Production in Taiwan

Covestro has launched localised production of medical-grade Thermoplastic Polyurethane (TPU) at its Changhua site in Taiwan, marking its first such facility in the Asia Pacific region. The site, now qualified for medical-grade TPU manufacturing, will produce Desmopan® Rx grades, enabling faster and more secure regional supply for high-performance medical applications.

This is Covestro’s second global site after New Martinsville, North America, to manufacture medical-grade TPU. The move reflects rising demand driven by improved healthcare standards and an ageing global population.

Meeting Global Standards, Serving Regional Needs

Manufactured in line with Good Manufacturing Practice (GMP) guidelines, Desmopan® Rx grades meet international medical standards including ISO 10993 and China’s YY/T 1557, ensuring biocompatibility and minimised contamination risks. Free from added plasticisers, the TPU grades offer low extractables and are compatible with multiple sterilisation methods.

Dr Frank Yang, Head of Asia-Pacific Innovation TPU at Covestro, stated: “Our Desmopan® Rx grades meet established medical industry standards. This production shift ensures product safety, compliance, and timely delivery for regulated Asian markets.”

Designed for Advanced Medical Use

Desmopan® Rx TPUs are tailored for a wide range of medical devices, including tubing, catheters, connectors, housings, endoscopes, and wearable devices. Their use spans surgical procedures, drug delivery, dialysis, wound care, and more.

The material’s benefits include:

  • Biocompatibility for patient-contact use
  • High clarity for medical observation
  • Kink resistance for uninterrupted fluid flow
  • Excellent chemical and abrasion resistance
  • Superior flexibility and dimensional stability

Additionally, Desmopan® Rx is suitable for melt-blown medical nonwovens used in drapes, gowns, sterile packaging, and PPE, offering strong performance while complying with medical waste regulations.

Strengthening Regional Infrastructure

The Changhua facility complements Covestro’s Zhuhai production base and its new application development centre in Guangzhou, enhancing local innovation and delivery capabilities. Kevin Ho, Head of Sales and Market Development TPU Asia Pacific, noted, “With Changhua online, we can now shorten lead times and improve supply reliability for the region.”

Covestro is showcasing the Desmopan® Rx range at Booth N5E24 during CPHI & PMEC China, running through 26 June at the Shanghai New International Expo Center.

Covestro has launched localised production of medical-grade Thermoplastic Polyurethane (TPU) at its Changhua site in Taiwan, marking its first such facility in the Asia Pacific region. The site, now qualified for medical-grade TPU manufacturing, will produce Desmopan® Rx grades, enabling faster and more secure regional supply for high-performance medical applications.This is Covestro’s second global site after New Martinsville, North America, to manufacture medical-grade TPU. The move reflects rising demand driven by improved healthcare standards and an ageing global population.Meeting Global Standards, Serving Regional NeedsManufactured in line with Good Manufacturing Practice (GMP) guidelines, Desmopan® Rx grades meet international medical standards including ISO 10993 and China’s YY/T 1557, ensuring biocompatibility and minimised contamination risks. Free from added plasticisers, the TPU grades offer low extractables and are compatible with multiple sterilisation methods.Dr Frank Yang, Head of Asia-Pacific Innovation TPU at Covestro, stated: “Our Desmopan® Rx grades meet established medical industry standards. This production shift ensures product safety, compliance, and timely delivery for regulated Asian markets.”Designed for Advanced Medical UseDesmopan® Rx TPUs are tailored for a wide range of medical devices, including tubing, catheters, connectors, housings, endoscopes, and wearable devices. Their use spans surgical procedures, drug delivery, dialysis, wound care, and more.The material’s benefits include:Biocompatibility for patient-contact useHigh clarity for medical observationKink resistance for uninterrupted fluid flowExcellent chemical and abrasion resistanceSuperior flexibility and dimensional stabilityAdditionally, Desmopan® Rx is suitable for melt-blown medical nonwovens used in drapes, gowns, sterile packaging, and PPE, offering strong performance while complying with medical waste regulations.Strengthening Regional InfrastructureThe Changhua facility complements Covestro’s Zhuhai production base and its new application development centre in Guangzhou, enhancing local innovation and delivery capabilities. Kevin Ho, Head of Sales and Market Development TPU Asia Pacific, noted, “With Changhua online, we can now shorten lead times and improve supply reliability for the region.”Covestro is showcasing the Desmopan® Rx range at Booth N5E24 during CPHI & PMEC China, running through 26 June at the Shanghai New International Expo Center.

Related Stories

Gold Stories

Next Story
Infrastructure Transport

Mumbai-Ahmedabad Bullet Train’s Surat-Vapi Section Set for 2027

The first section of the Mumbai-Ahmedabad Bullet Train corridor, linking Surat and Vapi, is targeted to begin services in 2027. Construction is expected to be completed by December 2026, while Railway Minister Ashwini Vaishnaw has indicated that an inauguration could take place around the middle of 2027. The National High Speed Rail Corporation (NHSRCL) said the train being manufactured in India is expected to reach the tracks around April or May 2027. The train will undergo extensive testing before the section is opened for passenger services. The project began construction in 2021 and includ..

Next Story
Infrastructure Transport

Indian Railways Approves Four Projects Worth Rs. 7.36 bn Across Four States

Indian Railways has approved four projects with a combined value of Rs. 7.36 bn across Uttar Pradesh, Maharashtra, Andhra Pradesh and Gujarat. The programme covers train protection, signalling, electric traction supply and a road overbridge, with each project assigned to a different railway zone. In Uttar Pradesh, Rs. 2.52 bn has been approved to extend the Kavach 4.0 automatic train protection system across 607.7 km in the Lucknow Division of North Eastern Railway. The system monitors train movements and can apply the brakes if a driver fails to observe a signal or exceeds a safe speed. The w..

Next Story
Infrastructure Urban

Chandru Raheja Sells 1.49% Stake in Mindspace REIT for Rs. 5 bn

Billionaire Chandru Lachmandas Raheja has sold a 1.49 per cent holding in Mindspace Business Parks REIT for Rs. 5 bn through a bulk deal on the BSE. The transaction involved 9.9 mn units and was executed at an average price of Rs. 505 per unit, according to exchange data. Following the sale, units of Mindspace Business Parks REIT were trading 0.18 per cent lower at Rs. 504.05 on Tuesday. Exchange data did not identify the buyers involved in the transaction. Raheja is the chairman of real estate company K Raheja Corp. The sale involved 99,00,990 units, representing 1.49 per cent of the Mumbai-b..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code